Corrigendum
- PMID: 38214122
- DOI: 10.2217/fon-2022-0913c1
Corrigendum
Erratum for
-
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22. Future Oncol. 2022. PMID: 36946237
Publication types
LinkOut - more resources
Full Text Sources